Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. The report states ...

UK privately-held T-regulatory (Treg) cell therapies developer Quell Therapeutics today revealed that pharma major ...

A fresh attempt to bring more pharmaceutical manufacturing back to US soil has put the sector on alert, as a new executive ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly ...

Oxford, UK-based biotech SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease ...

Privately-owned German biotech XL-protein GmbH today announced that it has entered into a worldwide license, development and ...

UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO).

Africa is grappling with a worsening mpox crisis, with a critical shortfall of vaccine doses threatening to derail ...

German science and technology firm Merck KGaA (MRK: DE) has moved a step closer to introducing a new therapy for tenosynovial ...

Swiss pharma company Idorsia (SIX: IDIA) today announced the appointment of Dr Srishti Gupta as chief executive (CEO), ...

Specialty immunotherapy company Tevogen Bio Holdings has announced the execution of a lease agreement to expand its corporate ...

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...